Please login to the form below

Not currently logged in
Email:
Password:

Restricting marketing to trainee doctors can create scepticism

A US study finds that restricting marketing to trainee doctors can negatively affect their attitudes to the pharmaceutical industry

A US study has found that restricting marketing to trainee doctors can negatively affect their attitudes to the pharmaceutical industry.

Despite the rise in direct-to-consumer advertising in the US media, the majority of the USD 21bn that pharmaceutical companies spend annually on marketing targets doctors, training doctors and medical students.

According to research conducted by the Indiana University Medical School and the Regenstrief Institute, a review of recent medical literature published in the December 2007 issue of 'Paediatrics' found that seminars, role-playing and other strategies could positively affect the medical community's attitudes and behaviour toward drug companies.

The study author, Dr Aaron E Carroll, assistant professor of paediatrics with Children's Health Services Research, revealed that policies restricting contact between medical trainees and the pharmaceutical industry led to more scepticism about information provided by drug company sales representatives and altered future behaviour in interactions with those reps.

In a press statement, Carroll said: "Doing nothing is no longer an acceptable option. Medical schools need to bring up the complex financial, medical and ethical issues involved in the interactions between doctors and drug companies."

4th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics